The Geneva Antibody Platform joins the LTA!

The services offered allow the development of new recombinant antibodies against any target using the “phage display” technique. In addition, the platform provides access to the ABCD database listing more than 15’000 recombinant antibodies and their targets and can produce, in mammalian cells, all antibodies with known sequences. Hybridomas (cells producing monoclonal antibodies) can be sequenced and these sequences converted into recombinant antibodies.

More informations …